Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study

• Published in: Veterinary medicine and science Vol. 10; no. 3; pp. e1454 - n/a
• Main Authors: An, Ju‐Hyun, Choi, Han‐Sol, Choi, Ji‐Soo, Lim, Hyun‐Woo, Huh, Wan, Oh, Ye‐In, Park, Joon Seok, Han, Jumi, Lim, Soo, Lim, Chae‐Young, Kim, Tae‐Hee, Moon, Jae‐Bong, Youn, Hwa‐Young
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2024; John Wiley and Sons Inc; Wiley
• Subjects: Animals; Benzofurans; Blood glucose; Blood levels; Blood pressure; Clinical trials; Diabetes; diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes Mellitus - drug therapy; Diabetes Mellitus - veterinary; Diuretics; Dog Diseases - drug therapy; DOGS; Dosage; Drug dosages; Drug Therapy, Combination - veterinary; DWP16001; Fasting; Female; Food consumption; Food intake; Glucose; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents - administration & dosage; Hypotheses; Insulin; Ketoacidosis; Male; Original; Patients; Pharmaceuticals; Pilot Projects; Prescription drugs; Side effects; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - administration & dosage; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; sodium‐glucose cotransporter‐2 inhibitor; Veterinary medicine; dogs; DWP16001; diabetes mellitus; sodium‐glucose cotransporter‐2 inhibitor
• ISSN: 2053-1095; 2053-1095
• DOI: 10.1002/vms3.1454

Background Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are a novel class of anti‐hyperglycaemic agents. Objective This study aimed to evaluate the safety and the adjuvant glycaemic control effect of an SGLT2 inhibitor, DWP16001, in diabetic dogs receiving insulin treatment. Methods Nineteen diabetic dogs receiving insulin treatment (NPH, porcine lente and glargine insulin) were divided into two groups according to dosing frequency: DWP TOD group (n = 10) and DWP SID group (n = 9). In the DWP TOD group, 0.025 mg/kg of DWP16001 was administered once every 3 days, whereas, in the DWP SID group, 0.025 mg/kg of DWP16001 was administered once a day. Food intake was maintained during the trial period. Hypoglycaemia, ketoacidosis or unexpected life‐threatening reactions were assessed as adverse effects before and after DWP16001 administration. We compared insulin requirement reduction and blood glucose level control between two groups. Results No specific adverse effects were observed during the clinical trial, and haematological parameter remained unchanged. Moreover, the fasting glucose levels and daily insulin dose in the DWP TOD group were lower than the pre‐administration values, but not significantly different for 8 weeks. Systolic blood pressure, fructosamine and insulin dose decreased significantly in the DWP SID group compared to the DWP TOD group at 8 weeks (p < 0.05) without affecting food consumption. Among these patients, 10 patients were monitored while receiving DWP16001 for 12 months (DWP TOD group n = 5, DWP SID group n = 5). The fasting glucose and fructosamine levels and daily insulin dose were reduced in both groups at 12 months compared with those before receiving DWP16001. Conclusion When DWP16001, an SGLT2 inhibitor, was supplied to dogs with type 1 diabetes, no adverse effects were observed, and it was confirmed that the administered insulin dose can be reduced in controlling blood glucose. Administration of the SGLT2 inhibitor, DWP16001, can be an adjunctive method for managing diabetes in terms of glycaemic control without adverse effects in diabetic dogs receiving insulin therapy. This study will serve as the primary basis for the application of SGLT2 inhibitors in dogs with insulin‐dependent diabetes mellitus.